Sustained Intratumoral Administration of Agonist CD40 Antibody Overcomes Immunosuppressive Tumor Microenvironment in Pancreatic Cancer (Adv. Sci. 9/2023)

Intratumoral Immunotherapy for Pancreatic Cancer In article number 2206873, Hsuan-Chen Liu, Corrine Ying Xuan Chua, Alessandro Grattoni, and co-workers leveraged a nanofluidic implant to demonstrate the efficacy of sustained intratumoral CD40Ab immunotherapy against pancreatic adenocarcinoma. The intratumoral strategy transformed the tumor immune microenvironment to a phenotype conducive to tumor elimination without systemic toxicity and achieved abscopal response against distant untreated tumors.